公开(公告)号：US11918650B2

公开(公告)日：2024-03-05

申请号：US15972489

申请日：2018-05-07

申请人： AMGEN INC.

发明人： Jeff Abel ,  Lingwen Cui ,  Devrishi Goswami ,  Joon Huh ,  Bharadwaj Jagannathan ,  Sekhar Kanapuram ,  Arnold McAuley ,  Michael Schneider ,  Ananthakrishnan G. Sethuraman ,  Michael Treuheit ,  Jun Zhang

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/24 ,  A61K47/26 ,  C07K16/28 ,  C07K16/46 ,  A61J1/05 ,  A61J1/10 ,  A61K39/00

CPC分类号： A61K39/39591 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/183 ,  A61K47/24 ,  A61K47/26 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/468 ,  A61J1/05 ,  A61J1/10 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/627 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/569

摘要： The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.

公开(公告)号：US11904143B2

公开(公告)日：2024-02-20

申请号：US16609466

申请日：2018-06-04

申请人： AMGEN INC.

发明人： Adam B. McCullough ,  Ronald Forster ,  Joseph Michael Iglesias ,  Matias Melander ,  Rasmus Øhlenschlaeger ,  Christian Plambech ,  Lars Stenholt ,  Bjarke Lykke Ludvig Svendsen

IPC分类号： A61M5/31 ,  A61M5/315 ,  A61M5/20

CPC分类号： A61M5/3145 ,  A61M5/20 ,  A61M5/31583 ,  A61M2005/3143

摘要： An injector includes a housing having a syringe assembly and an actuating mechanism at least partially disposed within the housing. The syringe assembly includes a syringe barrel that stores a medicament to be injected into a user, a needle assembly, and a filter member disposed adjacent to the needle assembly. The actuating mechanism is operatively coupled to the syringe assembly and includes a torque spring that exerts a torque to urge the medicament through the filter member to be injected into the user. The actuating mechanism further includes a damper mechanism that exerts an opposing force to dampen the motion exerted by the torque spring.

公开(公告)号：US20240043939A1

公开(公告)日：2024-02-08

申请号：US18380117

申请日：2023-10-13

申请人： Daiichi Sankyo Co., Ltd. ,  U3 Pharma GmbH ,  Amgen, Inc.

发明人： Matthias SCHNEIDER ,  Sabine BLUM ,  Renee Jeanne MENDELL-HARARY ,  Daniel J. FREEMAN ,  Robert Allen BECKMAN ,  Xiaoping JIN

IPC分类号： C12Q1/6886 ,  C07K16/32 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC分类号： C12Q1/6886 ,  C07K16/32 ,  C07K16/2863 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505

摘要： The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.

公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

申请人： AMGEN INC.

发明人： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC分类号： C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC分类号： C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

摘要： The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20240028790A1

公开(公告)日：2024-01-25

申请号：US18256442

申请日：2021-12-22

申请人： AMGEN INC. ,  Board of Regents, The University of Texas System

发明人： Tian Wu ,  Michael Schneider ,  Ryan Khalaf ,  Hugh Smyth ,  Ashlee Brunaugh ,  Li Ding

IPC分类号： G06F30/20

CPC分类号： G06F30/20

摘要： A forecasting modeling computing system includes a processors and a memory including a set of computer-executable instructions that, when executed by the processor, cause the forecasting modeling computing system to receive design parameters, determine a predicted median particle size, identify a predictive quadratic model, and display a response surface visualization. A computer-implemented method includes receiving design parameters, determining a predicted median particle size, identifying a predictive quadratic model; and display a response surface visualization.

公开(公告)号：US20240024579A1

公开(公告)日：2024-01-25

申请号：US18374288

申请日：2023-09-28

申请人： AMGEN INC.

发明人： Scott R. Gibson ,  Sheldon Moberg

IPC分类号： A61M5/20 ,  A61M5/24 ,  A61M5/32

CPC分类号： A61M5/20 ,  A61M5/24 ,  A61M5/3243 ,  A61M2005/2013 ,  A61M5/3202

摘要： A device, method, and system for drug delivery includes a casing for housing a drug storage container, the drug storage container including a dose delivery member, at least a portion of the dose delivery member extending through an opening in the casing; a guard movable relative to the casing between extended and retracted positions, the portion of the dose delivery member being surrounded by the guard in the extended position and the portion of the dose delivery member being at least partially exposed when the guard is in the retracted position; an interference arrangement for providing selected threshold of resistance to movement of the guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the detent arrangement having a first member associated with a surface within the casing, and a second member extending from the guard, the first and second members engaging one another to retain the guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another to allow the guard to move into the retracted position when the device is pressed toward the injection site during insertion of the dose delivery member.

公开(公告)号：US11873343B2

公开(公告)日：2024-01-16

申请号：US17529794

申请日：2021-11-18

申请人： AMGEN INC.

发明人： Stephen Robert Brych ,  Lyanne M. Wong ,  Jaymille Fallon ,  Monica Michelle Goss ,  Jian Hua Gu ,  Pavan K. Ghattyvenkatakrishna

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2875 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76

摘要： Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

公开(公告)号：US11872374B2

公开(公告)日：2024-01-16

申请号：US16951987

申请日：2020-11-18

申请人： AMGEN INC.

发明人： Scott R. Gibson ,  Sheldon Moberg

IPC分类号： A61M5/20 ,  A61M5/24 ,  A61M5/32

CPC分类号： A61M5/20 ,  A61M5/24 ,  A61M5/3243 ,  A61M5/3202 ,  A61M2005/2013

摘要： A device and method for drug delivery includes a casing for housing a drug storage container, the container including a dose delivery member, at least a portion of the dose delivery member extending through an opening in the casing; a guard movable relative to the casing between extended and retracted positions; an interference arrangement for providing selected threshold of resistance to movement of the guard from the extended position to the retracted position during insertion of the dose delivery member into body tissue at an injection site, the arrangement having a first member and a second member, the first and second members engaging one another to retain the guard in the extended position, one of the first and second members moving if the selected threshold of resistance is exceeded to allow the members to slide past one another to allow the guard to move into the retracted position.

公开(公告)号：US11866508B2

公开(公告)日：2024-01-09

申请号：US17142850

申请日：2021-01-06

申请人： AMGEN INC.

发明人： William Christian Fanslow, III ,  Carl Kozlosky ,  Jean Gudas

IPC分类号： A61K39/00 ,  C07K16/30 ,  C07K16/46 ,  G01N33/68 ,  C07K16/28

CPC分类号： C07K16/30 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/3046 ,  C07K16/468 ,  G01N33/6893 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.

公开(公告)号：US20240002545A1

公开(公告)日：2024-01-04

申请号：US18252442

申请日：2021-11-09

申请人： AMGEN INC.

发明人： Timothy RILEY ,  Fernando GARCES ,  Zhulun WANG ,  Bram Estes ,  Darren L. Bates

IPC分类号： C07K16/46

CPC分类号： C07K16/468 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/31

摘要： The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.